Macleod M, Slattery J, Grant R
Department of Clinical Neurosciences, Western General Hospital, Edinburgh, UK.
Br J Neurosurg. 1995;9(5):653-7. doi: 10.1080/02688699550040945.
The sensitivity of three scales of performance and handicap to the presence and development of epilepsy in patients with brain tumours was studied. Two hypothetical cases had equivalent disability, in one case due to epilepsy and in the other to physical impairment. The second case later developed epilepsy. All consultant neurologists and neurosurgeons in Scotland were asked to grade the cases using three scales commonly used for patients with cerebral glioma. Consultants rated the patient with epilepsy alone as being less disabled and handicapped than the patient with physical impairment without seizures (sign test p < 0.003). At best 21% of clinicians (p = 0.03) were able to report a change in performance score in the second case when seizures developed. These scales do not reflect changes in handicap and performance associated with tumour associated epilepsy. Clinical trial protocols for treatments for brain tumours must state how performance and handicap related to epilepsy will be measured.
研究了三种功能和残疾量表对脑肿瘤患者癫痫的存在和发展的敏感性。两个假设病例具有同等程度的残疾,一个病例是由于癫痫,另一个病例是由于身体损伤。第二个病例后来发展为癫痫。研究人员要求苏格兰所有的神经科和神经外科会诊医生使用三种常用于脑胶质瘤患者的量表对这些病例进行分级。会诊医生将仅患有癫痫的患者评定为比没有癫痫发作的身体损伤患者残疾程度和障碍程度更低(符号检验p<0.003)。在第二种情况下癫痫发作时,最多只有21%的临床医生(p = 0.03)能够报告功能评分的变化。这些量表没有反映出与肿瘤相关性癫痫相关的残疾和功能变化。脑肿瘤治疗的临床试验方案必须说明将如何测量与癫痫相关的功能和残疾情况。